Tonix Reports Breakthrough in Organ Transplant Therapy With Promising New Drug TNX-1500
Tonix Pharmaceuticals has reported positive phase one results for TNX-1500, a monoclonal antibody designed to prevent organ transplant rejection and treat autoimmune diseases. CEO Dr. Seth Lederman explained that TNX-1500
